World's Best Scientists 2026 revealed!
Award Badge
Medicine
Germany
2026

D-Index & Metrics

Medicine

D-Index
134
Citations
63598
World Ranking
2158
National Ranking
104

Hermann Einsele publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Hermann Einsele sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 937 publications — 93rd percentile

93% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Hermann Einsele D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Hermann Einsele sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 134 D-Index — 90th percentile

90% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Medicine in Germany Leader Award
  • 2023 - Research.com Medicine in Germany Leader Award

Overview

Hermann Einsele is affiliated with the University of Würzburg in Germany. Their research primarily focuses on medical fields related to hematology, immunology, molecular biology, oncology, and epidemiology.

The scientist's main research topics include:

  • CAR-T cell therapy research
  • Immune Cell Function and Interaction
  • Protein Degradation and Inhibitors
  • Cytomegalovirus and herpesvirus research
  • Herpesvirus Infections and Treatments
  • Parvovirus B19 Infection Studies
  • Acute Myeloid Leukemia Research

Hermann Einsele has published extensively in the field of medicine, with 31 publications spanning related subfields such as immunology, epidemiology, molecular biology, oncology, and hematology. Their work has appeared frequently in several scientific journals and venues, including:

  • Blood (4 publications)
  • The Lancet Infectious Diseases (2 publications)
  • Best Practice & Research Clinical Haematology (2 publications)
  • Cell Death Discovery (1 publication)
  • Cellular Oncology (1 publication)

Notable papers authored by Hermann Einsele include:

  • How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation, 2020, Blood
  • Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants: guidelines from the 8th European Conference on Infections in Leukaemia, 2022, The Lancet Infectious Diseases
  • Recommendations from the 10th European Conference on Infections in Leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies, 2025, The Lancet Infectious Diseases
  • Therapeutic advances in the targeting of ROR1 in hematological cancers, 2024, Cell Death Discovery
  • Looking ahead to targeting macrophages by CAR T- or NK-cells in blood cancers, 2024, Expert Opinion on Therapeutic Targets

Frequent co-authors collaborating with Hermann Einsele include:

  • Dávid Kegyes
  • Rafael de la Cámara
  • Adrian Bogdan Țigu
  • Raluca Munteanu
  • Diana Gulei

Best Publications

  • Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

    Marcie Tomblyn;Tom Chiller;Hermann Einsele;Ronald Gress

  • Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

    Nikhil C Munshi;Larry D Anderson;Nina Shah;Deepu Madduri

  • The landscape of genomic alterations across childhood cancers

    Susanne N. Gröbner;Barbara C. Worst;Joachim Weischenfeldt;Joachim Weischenfeldt;Ivo Buchhalter

  • Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

    Abstr Act;Sagar Lonial;Meletios Dimopoulos;Antonio Palumbo

  • Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody

    Ralf Bargou;Eugen Leo;Gerhard Zugmaier;Matthias Klinger

  • Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

    Max S. Topp;Peter Kufer;Nicola Gökbuget;Mariele Goebeler

  • Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

    Jesús F. San-Miguel;Vânia T.M. Hungria;Sung Soo Yoon;Meral Beksac

  • Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

    Pieter Sonneveld;Hervé Avet-Loiseau;Sagar Lonial;Saad Usmani

  • Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy.

    Hermann Einsele;Eddy Roosnek;Nathalie Rufer;Christian Sinzger

  • Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial

    Jürgen Finke;Wolfgang A Bethge;Claudia Schmoor;Hellmut D Ottinger

  • Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer

    Volker Heinemann;Detlef Quietzsch;Frank Gieseler;Michael Gonnermann

  • Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

    Antonio Palumbo;Sara Bringhen;Maria Victoria Mateos;Alessandra Larocca

  • Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).

    Roswitha Forstpointner;Michael Unterhalt;Martin Dreyling;Hans-Peter Böck

  • Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation.

    Tobias Feuchtinger;Kathrin Opherk;Wolfgang A. Bethge;Max S. Topp

  • Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

    Max S. Topp;Nicola Gökbuget;Gerhard Zugmaier;Evelyn Degenhard

  • Autologous Stem-Cell Transplantation As First-Line Therapy in Peripheral T-Cell Lymphomas: Results of a Prospective Multicenter Study

    Peter Reimer;Thomas Rüdiger;Eva Geissinger;Florian Weissinger

  • Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

    Nicolaus Kröger;Ernst Holler;Guido Kobbe;Martin Bornhäuser

  • Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

    Michele Cavo;Evangelos Terpos;Cristina Nanni;Philippe Moreau

  • Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

    Christoph Röllig;Hubert Serve;Andreas Hüttmann;Richard Noppeney

  • The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells

    Katrin Mestermann;Theodoros Giavridis;Justus Weber;Julian Rydzek

Frequent Co-Authors

Holger Hebart
Holger Hebart University of Tübingen
Pieter Sonneveld
Pieter Sonneveld Erasmus University Rotterdam
Lothar Kanz
Lothar Kanz University of Tübingen
Meletios A. Dimopoulos
Meletios A. Dimopoulos National and Kapodistrian University of Athens
Stefan W. Krause
Stefan W. Krause University of Erlangen-Nuremberg
Andreas Rosenwald
Andreas Rosenwald University of Würzburg
Hartmut Goldschmidt
Hartmut Goldschmidt University Hospital Heidelberg
Michele Cavo
Michele Cavo University of Bologna

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring allied health fields or support roles can be a smart way to begin your medical career. Many choose to start with in-demand programs like the best medical billing and coding schools online, which offer flexible schedules and financial aid for those interested in the administrative side of healthcare.

Nursing also remains a highly rewarding field, with a growing number of accessible options. For example, there are now lpn to rn programs without teas test requirements, making it easier for Licensed Practical Nurses to advance their credentials quickly.

Aspiring healthcare leaders can accelerate their careers through a health care administration degree online, designed for those looking to enter management roles within hospitals, clinics, or insurance companies.

Registered Nurses who wish to become Family Nurse Practitioners may consider specialized adn to fnp bridge programs that offer a streamlined pathway to advanced practice.

These online pathways are ideal for students and working professionals who need flexibility as they build careers in the ever-evolving healthcare field.

Best Scientists Citing Hermann Einsele

Trending Scientists

Recently Published Articles